Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

Effect of imatinib on growth in children with chronic myeloid leukemia (Boddu D et al. Pediatr Hematol Oncol, July 2019)

Effect of imatinib on growth in children with chronic myeloid leukemia
Boddu D et al. Pediatr Hematol Oncol, July 2019 (epub ahead of print)

Targeting autophagy potentiates the anti-tumor effect of PARP inhibitor in pediatric chronic myeloid leukemia (Liu Y et al. AMB Express, July 2019)

Targeting autophagy potentiates the anti-tumor effect of PARP inhibitor in pediatric chronic myeloid leukemia
Liu Y et al. AMB Express, July 2019

Favourable of de novo advanced phases of childhood chronic myeloid leukemia (Millot F et al. Eur J Cancer, May 2019)

Favourable de novo advanced phases of childhood chronic myeloid leukemia
Eur J Cancer, May 2019 (epub ahead of print)
Millot F et al. 

Large amplicon droplet PCR for DNA-based monitoring of pediatric chronic myeloid leukaemia (Krumbholz M et al. J Cell Mol Med, June 2019)

Large amplicon droplet PCR for DNA-based monitoring of pediatric chronic myeloid leukaemia
J Cell Mol Med, June 2019 (epub ahead of print)
Krumbholz M et al.

How I treat chronic myeloid leukemia in children and adolescents (Hijiya N et al. Blood, March 2019)

How I treat chronic myeloid leukemia in children and adolescents
Blood, March 2019 (epub ahead of print)
Hijiya N et al. 

  1. Discontinuation of imatinib in children with chronic myeloid leukaemia in sustained deep molecular remission: results of the STOP IMAPED study (de Bruin CMA et al. Br J Hematol, March 2019)
  2. Dasatinib: A review in pediatric chronic myeloid leukemia (McCafferty EH et al. Paediatric Drugs, November 2018)
  3. Pediatric chronic myeloid leukemia presenting with extreme thrombocytosis simulating essential thrombocythemia (Boklan JL et al. J Pediatr Hematol Oncol, April 2018)
  4. Early response does not predict outcome in children and adolescents with chronic myeloid leukemia treated with high-dose imatinib (Giona F et al. Br J Hematol, March 2018) (2)